JP Morgan Chase
BCLI

JP Morgan Chase’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

JP Morgan Chase’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-171
Closed -$215 – 7076
2025
Q1 		$215 Buy
171
+166
+3,320% +$294 ﹤0.01% 6791
2024
Q4 		$11 Sell
5
-7
-58% -$13 ﹤0.01% 7308
2024
Q3 		$40 Sell
12
-5
-29% -$24 ﹤0.01% 7154
2024
Q2 		$86 Buy
17
+10
+143% +$75 ﹤0.01% 6916
2024
Q1 		$60 Buy
7
+2
+40% +$11 ﹤0.01% 6995
2023
Q4 		$19 Buy
5
+2
+67% +$6 ﹤0.01% 7355
2023
Q3 		$8 Buy
3
+2
+200% +$45 ﹤0.01% 7313
2023
Q2 		$21 Sell
1
-198
-99% -$8.21K ﹤0.01% 6788
2023
Q1 		$10K Buy
+199
New +$5.77K ﹤0.01% 6112
2022
Q3 		– Sell
-12,471
Closed -$516K – 6455
2022
Q2 		$516K Sell
12,471
-3,942
-24% -$178K ﹤0.01% 4529
2022
Q1 		$827K Buy
16,413
+3,535
+27% +$174K ﹤0.01% 4401
2021
Q4 		$773K Sell
12,878
-16,835
-57% -$829K ﹤0.01% 4564
2021
Q3 		$1.47M Sell
29,713
-16,840
-36% -$886K ﹤0.01% 4019
2021
Q2 		$2.65M Sell
46,553
-7,143
-13% -$382K ﹤0.01% 3585
2021
Q1 		$3.08M Buy
53,696
+27,535
+105% +$2.08M ﹤0.01% 3371
2020
Q4 		$1.78M Buy
26,161
+25,451
+3,585% +$3.47M ﹤0.01% 3562
2020
Q3 		$172K Buy
710
+112
+19% +$22.9K ﹤0.01% 4428
2020
Q2 		$101K Sell
598
-4,267
-88% -$460K ﹤0.01% 4565
2020
Q1 		$339K Buy
4,865
+4,731
+3,531% +$369K ﹤0.01% 4028
2019
Q4 		$9K Buy
+134
New +$7.77K ﹤0.01% 5401
2018
Q4 		– Sell
-6,900
Closed -$395K – 5683
2018
Q3 		$395K Sell
6,900
-1,772
-20% -$107K ﹤0.01% 4387
2018
Q2 		$507K Buy
+8,672
New +$510K ﹤0.01% 4168
2017
Q4 		– Sell
-1,106
Closed -$68K – 5425
2017
Q3 		$68K Buy
+1,106
New +$71.6K ﹤0.01% 4404

Other funds holding BCLI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gunderson Capital Management Mt. Pleasant, South Carolina $370M AUM 211.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $592M AUM 25.27% 1-Year Est. Return

JP Morgan Chase's BCLI Position: Q2 2025 in Review

JP Morgan Chase sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2025, closing a stake of 171 shares — an estimated $215 sold.

JP Morgan Chase first reported a position in BCLI in Q3 2017 and held it in 23 quarters. The position peaked at $3.08M in Q1 2021. 34 funds tracked by Wall St. Rank hold BCLI as of Q2 2025.

  • JP Morgan Chase reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 171 BRAINSTORM CELL THERAPUTC shares in Q2 2025, an estimated $215.
  • JP Morgan Chase first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 23 quarters.
  • JP Morgan Chase's BRAINSTORM CELL THERAPUTC position peaked at $3.08M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.